Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 4 sources · 3 days · First seen · Last updated
Sellas Life Sciences cancer vaccine clinical trials
Overview
Sellas Life Sciences reported successful results from its Phase 3 REGAL study for the peptide vaccine Galinpepimut-S (GPS), intended to treat acute myeloid leukemia (AML). The study met its primary endpoint of statistically significant overall survival, showing a median survival of 24.0 months for the GPS group compared to 14.7 months for the comparison therapy. Following this announcement, the company experienced significant stock volatility.
Subsequent details clarified that the trial, conducted in collaboration with Memorial Sloan Kettering Cancer Center, included 126 patients who had achieved a second or subsequent complete remission. The vaccine reportedly reduced the risk of death by 41% compared to other treatments. Unlike personalized mRNA vaccines, GPS is described as an off-the-shelf formulation that does not require individual redesign for every patient.
Entities
Galinpepimut-S · SLS009 · Nasdaq · Memorial Sloan Kettering Cancer Center · SELLAS Life Sciences Group, Inc.
Timeline
-
[HEALTH] 2 sourcesGalinpepimut-S vaccine reduces leukemia death risk by 41%
A Phase 3 clinical trial for the galinpepimut-S (GPS) vaccine showed a 41% reduction in death risk for patients with acute myeloid leukemia.
-
[BUSINESS] 2 sourcesSellas Life Sciences reports Phase 3 success for cancer vaccine
Sellas Life Sciences reported that its Phase 3 REGAL study for the Galinpepimut-S cancer vaccine met its primary endpoint, showing significant improvements in overall survival for acute myeloid leukemia.
Sources
ad-hoc-news.de · aktiencheck.de · lifo.gr · tvxs.gr